Table 1.
Patient characteristics
| IgM neuropathy patients | ||||||
|---|---|---|---|---|---|---|
| Variables | Demyelinating, n = 25 | Axonal, n = 7 | Total, n = 32 | CIDP disease controls, n = 42 | CAP disease controls, n = 32 | P value |
| Age, median (IQR), y | 66 (61‐69) | 67 (60‐73) | 66 (61‐71) | 62 (51‐69) | 62 (54‐68) | .11 |
| Sex, men/women, n | 19/6 | 7/0 | 26/6 | 28/14 | 26/6 | .23 |
| Disease duration, median (IQR), mo | 26 (23‐90) | 48 (18‐73) | 36 (22‐81) | 12 (5‐29) | 18 (11‐48) | .002* |
| Clinical features, n (%) | ||||||
| Distal symmetric | 24/25 (96) | 6/7 (86) | 30/32 (94) | 20/42 (48) | 32/32 (100) | <.001* |
| Proximal and distal symmetric | 1/25 (4) | 1/7 (14) | 2/32 (6) | 22/42 (52) | 0 (0) | <.001* |
| Sensory dominant | 6/25 (24) | 3/7 (43) | 9/32 (28) | 8/42 (19) | 21/32 (66) | <.001* |
| Sensorimotor | 18/25 (72) | 3/7 (43) | 21/32 (66) | 11/42 (26) | 11/32 (34) | <.001* |
| Motor dominant | 1/25 (4) | 1/7 (14) | 2/32 (6) | 23/42 (55) | 0 (0) | <.001* |
| MRC sum‐score, median (IQR) | 117 (110‐118) | 117 (114‐120) | 117 (111‐119) | 112 (101‐118) | 120 (118‐120) | .009* |
Abbreviations: CAP, chronic axonal polyneuropathy; CIDP, treatment‐naive chronic inflammatory demyelinating polyneuropathy; IgM, immunoglobulin M; IgM neuropathy patients, patients with neuropathy and associated IgM monoclonal gammopathy of unknown significance; IQR, interquartile range; MRC sum‐score, Medical Research Council sum‐score of a predefined set of muscle groups bilaterally (range, 0‐120).
*
P < .05 significant difference.